Elcelyx Therapeutics is developing novel therapeutics based on Gut Sensory Modulation (GSM) science to address unmet needs in the pharmaceutical market. The company's lead proprietary product, metformin delayed-release (Metformin DR) has demonstrated clinical proof-of-concept for the treatment of type 2 diabetes. Further clinical development is planned to address two currently under-served patient populations: type 2 diabetes patients with moderate renal impairment and type 2 diabetes patients with gastrointestinal intolerance to metformin.
Metformin DR is being developed to potentially address the needs of the metformin intolerant and renally contraindicated type 2 sub-populations. ADA and EASD guidelines suggest that metformin is the preferred first agent for all patients with type 2 diabetes if not contraindicated and if tolerated. Metformin DR, by virtue of its unique delivery may have clinical utility in both populations.